La vendita allo scoperto per NexPoint Diversified Real dà agli investitori un'idea del grado in cui gli investitori stanno scommettendo sul declino delle azioni di NexPoint Diversified Real. I dati relativi alle vendite allo scoperto vengono aggiornati ogni due settimane.

NexPoint Diversified Real (NYSE:NXDT) Azioni, Report sulle vendite allo scoperto

NexPoint Diversified Real

NexPoint Diversified Real Estate Trust is a publicly traded REIT focused on opportunistic real estate investments in the United States. Their portfolio includes diverse commercial properties and investments across various real estate sectors and capital structures. The revenue sources of the company include rental income from office and retail properties, interest income from debt investments, dividend income from equity investments, and other ancillary income from tenants. The company operates through its operating partnership and wholly owned subsidiaries.

NexPoint Diversified Real Estate Trust Common Stock

NexPoint Diversified Real Estate Trust

NexPoint Diversified Real Estate Trust 5.50% Series A Cumulative Preferred Shares ($25.00 liquidation preference per share)

BWS Financial analyst Hamed Khorsand maintains Ubiquiti (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/UI#NYSE">UI</a>) with a Buy and maintains $440 price target.

News

Price Target

Analyst Ratings

BWS Financial Maintains Buy on Ubiquiti, Maintains $440 Price Target

Earnings

Earnings Beats

LINC

UPDATE: Lincoln Educational Servs Q1 Adj. EPS $0.11 Beats $0.04 Estimate,

<figure class="wp-block-image size-full"><img loading="lazy" decoding="async" width="900" height="600" src="https://contributor-assets.benzinga.com/wp-content/uploads/2025/05/12074321/Zhipu-0512-900x600-1.png" alt="" class="wp-image-12780" srcset="https://contributor-assets.benzinga.com/wp-content/uploads/2025/05/12074321/Zhipu-0512-900x600-1.png 900w,https://contributor-assets.benzinga.com/wp-content/uploads/2025/05/12074321/Zhipu-0512-900x600-1-300x200.png 300w,https://contributor-assets.benzinga.com/wp-content/uploads/2025/05/12074321/Zhipu-0512-900x600-1-768x512.png 768w" sizes="(max-width: 900px) 100vw, 900px" /></figure>
The company, which focuses on large language models for enterprise clients, has raised 2 billion yuan this year, from mostly government sources
<h4 class="wp-block-heading">Key Takeaways:</h4>
<ul class="wp-block-list">
<li>Zhipu AI is aiming to become the first of China's "AI tigers" to go public, as its competitors pivot away from costly foundational model development</li>
<li>The company relies heavily on government support, but such a strategy also carries risks, as other AI leaders have learned</li>
</ul>
Recognition or general knowledge?
That's the question confronting China's bumper crop of AI startups these days, as they try to chart a path that keeps them clear of controversy and overreliance on state support while also providing strong growth potential. While many of the earliest players focused on recognition AI that has found one of its biggest applications in surveillance, a newer generation of startups is finding bigger potential – and less controversy – in knowledge-based large language models (LLMs) like those from OpenAI and, more recently, DeepSeek.
Now, one of those,&nbsp;Zhipu AI,&nbsp;is aiming to become the first among a new group of pure LLM companies to go public, taking its first step towards an IPO by filing documentation with the Beijing Securities Regulatory Bureau last month,&nbsp;<a href="https://www.caixin.com/2025-04-15/102309642.html">according to</a>&nbsp;financial media Caixin. If the process goes smoothly, Zhipu could become the first of China's six " AI tigers" raised on knowledge-based LLMs to tap the public capital markets.
The company is widely regarded as one of the most likely survivors among these six players in China's fiercely competitive AI landscape. Their space in LLMs has been recently disrupted by DeepSeek, which has gained significant attention following its recent release of more cost-effective models, including its reasoning-focused R1.
Despite its recent sudden leap to fame, DeepSeek isn't considered one of the six AI tigers in LLMs. Among the other five –&nbsp;MiniMax,&nbsp;Moonshot,&nbsp;Baichuan,&nbsp;StepFun&nbsp;and&nbsp;01.AI&nbsp;– two have already signaled a strategic shift away from foundational model development, of which LLMs are a subset. 01.AI, founded by AI pioneer and prominent venture capitalist and former Google China chief Lee Kai-Fu, has indicated it will cease investing in the development of foundational models, which demands substantial investment in AI chips and R&amp;D.
Instead, these companies are pivoting toward developing applications based on foundational models developed by other companies like DeepSeek. Baichuan, founded by Wang Xiaochuan, former CEO of search engine Sougou, has similarly indicated a strategic pivot, focusing on healthcare applications rather than continuing investment in foundational models.
While the other three companies haven't commented on their strategies lately, Zhipu AI stands out with its unequivocal commitment to foundational model development. The company has recently doubled down on this approach, launching a general-purpose AI agent in March, powered by its proprietary GLM model. It has also&nbsp;<a href="https://www.reuters.com/technology/artificial-intelligence/chinas-zhipu-ai-launches-free-ai-agent-intensifying-domestic-tech-race-2025-03-31/">taken the additional step</a>&nbsp;of open-sourcing its foundational models, similar to DeepSeek.
<h4 class="wp-block-heading">State backing</h4>
Among the foundational AI tigers, Zhipu has demonstrated a noteworthy ability to raise funds. While its peers have been quiet on that front over the past year, Zhipu has emerged as an investor favorite, securing at least 2 billion yuan ($276 million) in fresh funds this year alone.
The fundraising streak began in early March when the municipal government of Hangzhou, capital of Zhejiang province, emerged as the lead investor in a 1 billion yuan funding round. This was followed by investments from three other Chinese cities: Zhuhai in Guangdong province contributed 500 million yuan; Chengdu, capital of Sichuan province, invested 300 million yuan; and most recently, the Beijing municipal government provided 200 million yuan.
The recent funding wave is noteworthy for being led by government-backed sources, as China moves aggressively to develop the sector. Zhipu's seizing on that largess marks a shift for the company from its previous reliance on private capital.
Founded in 2019 by Tsinghua University alumni Tang Jie and Zhang Peng, Zhipu AI began within the university's walls and was later spun off. Its early funding rounds attracted prominent private investors like HongShan – formerly Sequoia China – and Chinese internet giants such as Alibaba and Tencent. Its roots at China's most famous sciences university may be at least partly behind the recent flood of state capital to the company.
Zhipu was among China's pioneers in LLM development, founded before OpenAI's transformative release of ChatGPT in late 2022. The ChatGPT launch sparked an AI rush in China, leading to the emergence of numerous companies racing to develop Chinese alternatives. All of Zhipu's major competitors were established in this post-ChatGPT era.
The company's financial prowess is evident in its fundraising history. According to research firm RimeData, Zhipu has completed 14 funding rounds since its inception, raising over 9 billion yuan. Its ability to raise so much money, combined with its early focus on LLMs, has given Zhipu a leg up on its competitors in China's intensely competitive AI landscape.
However, Zhipu's real competition isn't coming from other AI startups, but rather from tech giants like&nbsp;Alibaba,&nbsp;ByteDance, and&nbsp;Tencent, as well as the fast-rising DeepSeek. While Zhipu boasts strong backing from both public and private sources, such established players command even greater financial resources from their highly profitable core businesses.
While AI commercialization remains in its early stages, the race to capture consumer market share reveals the current state of the market. Zhipu's Qingyan consumer app ranks ninth with 9 million monthly active users, significantly behind market leaders. Alibaba's Quark app leads the pack with 149 million monthly active users, followed by ByteDance's Doubao with 107 million and DeepSeek's 96 million, according to April data from AI product tracker Aicpb.com.
That said, consumer applications aren't Zhipu AI's primary focus. The company has positioned itself more strategically as a provider of customized AI solutions for enterprise clients and government organizations, which tend to be more profitable than consumers.
In China's technology market, government organizations, along with national and local state-owned enterprises, are some of the biggest spenders on software and digital solutions – which could work to Zhipu's advantage due to its strong government connections.
But such heavy government reliance carries its own risks. A cautionary tale can be found in the fate of the four "AI dragons" from the pre-ChatGPT era, when AI was primarily associated with recognition technology, in this case involving computer vision.
The four AI dragons –&nbsp;SenseTime&nbsp;(0020.HK),&nbsp;Megvii,&nbsp;CloudWalk&nbsp;(688327.SH) and&nbsp;Yitu&nbsp;–primarily built their businesses on government work, providing surveillance systems powered by computer vision technology. However, these companies have largely faded from prominence following government spending cuts in surveillance-related projects.
Unable to diversify their customer base or expand into new applications, these once-prominent AI companies now find themselves struggling with dwindling business and mounting losses. In a nod to that reality, SenseTime&nbsp;<a href="https://thebambooworks.com/time-for-a-shift-sensetime-formalizes-pivot-to-generative-ai/">has recently been</a>&nbsp;rapidly shifting its business away from its recognition technology roots, and moving towards foundational models with better commercial potential.
At the end of the day, Zhipu's substantial financial resources position it as a likely survivor as it competes against tech giants in China's fast-evolving AI landscape. Still, it faces a critical challenge as it prepares to become first in its class to list: demonstrating to investors it can generate sustainable revenue from its proprietary products and services.

Asia

Equities

IPOs

Opinion

Tech

The Race To Go Public Among New Gen Chinese 'AI Tigers'

D. Boral Capital analyst Jason Kolbert maintains UroGen Pharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/URGN#NASDAQ">URGN</a>) with a Buy and maintains $25 price target.

URGN

D. Boral Capital Maintains Buy on UroGen Pharma, Maintains $25 Price Target

IGC Pharma, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/IGC#NYSE">IGC</a>) ("IGC" or the "Company") today announced that it presented its latest scientific poster, titled "Genetic Toxicity Evaluation of Melatonin in the Bacterial Reverse Mutation Assay," at the <a href="https://pr.report/ab65">2025 Genetic Toxicology Association Annual Meeting</a>, showcasing key non-clinical data that support the genetic safety profile of one of the two active pharmaceutical ingredients ("API") in IGC-AD1, the Company's investigational drug for Alzheimer's disease.
Part of the FDA's battery of safety requirements is to show that APIs are safe for human consumption, including that they do not alter or mutate genes. IGC completed this requirement and is now able to show that the APIs in IGC-AD1 are safe and do not alter genes.

Biotech

General

IGC Pharma Presents Its Latest Scientific Poster, Titled "Genetic Toxicity Evaluation Of Melatonin In The Bacterial Reverse Mutation Assay," At The 2025 Genetic Toxicology Association Annual Meeting

Shares of Chinese electric vehicle (EV) maker XPeng Inc &#8211; ADR (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XPEV#NYSE">XPEV</a>) surged 7.7% to $21.15 Monday morning following news that the U.S. and China reached a temporary truce in their ongoing trade dispute, agreeing to significantly roll back tariffs on <a href="https://www.benzinga.com/markets/equities/25/05/45341884/apple-amazon-nvidia-rise-in-monday-premarket-as-us-china-agree-to-90-day-tariff-truce-neither-side-wants-a-decoupling">most goods for 90 days</a>.
What To Know: XPeng, an EV manufacturer based in Guangzhou, stands to benefit directly from the <a href="https://www.benzinga.com/topic/tariffs">tariff</a> reduction. The company has been aggressively expanding its footprint in Europe and exploring entry into the North American market.
With tariffs now lowered from 125% to just 10% on most categories, XPeng's cost structure for potential U.S. exports and imported U.S. components likely improves considerably.
Moreover, China's suspension of non-tariff countermeasures, including sanctions and export restrictions on high-tech materials, could ease XPeng's access to advanced semiconductors and batteries, critical to its XNGP autonomous driving platform and upcoming G6 and X9 models.
The easing of geopolitical tensions could also boost investor confidence in XPeng's international strategy and alleviates risks tied to supply chain disruptions and trade barriers.
Read Also: <a href="https://www.benzinga.com/trading-ideas/25/05/45327340/3-best-energy-stocks-to-buy-right-now">3 Best Energy Stocks To Buy Right Now</a>
<h2 class="wp-block-heading">How To Buy XPEV Stock</h2>
Besides going to a brokerage platform to purchase a share &#8211; or fractional share &#8211; of stock, you can also gain access to shares either by buying an exchange traded fund (ETF) that holds the stock itself, or by allocating yourself to a strategy in your 401(k) that would seek to acquire shares in a mutual fund or other instrument. 
For example, in XPeng&#8217;s case, it is in the Consumer Discretionary sector. An ETF will likely hold shares in many liquid and large companies that help track that sector, allowing an investor to gain exposure to the trends within that segment.
According to data from&nbsp;<a href="https://benzinga.grsm.io/register174">Benzinga Pro</a>, XPEV has a 52-week high of $27.16 and a 52-week low of $6.60.

XPEV

XPeng (XPEV) Stock Surges On US–China Tariff Easing: What's Going On?

MBX Biosciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MBX#NASDAQ">MBX</a>) reported quarterly losses of $(0.71) per share which beat the analyst consensus estimate of $(0.77) by 7.79 percent. This is a 93.08 percent increase over losses of $(10.26) per share from the same period last year.

MBX Biosciences Q1 EPS $(0.71) Beats $(0.77) Estimate

Jianzhi Education Technology Group Company Limited ("Jianzhi") (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/JZ#NASDAQ">JZ</a>), a leading provider of digital educational content in China, today announced it had partnered with China Telecom, one of the world's largest and most influential integrated communications and technology providers. This major collaboration represents a critical step forward in integrating Jianzhi's robust education platforms into China Telecom's expansive cloud center infrastructure.
Following extensive negotiations between the two organizations, this landmark collaboration aims to reshape the future of education by embedding cutting-edge AI-generated content (AIGC) and digital human technologies into every facet of the learning experience.
China Telecom, a Fortune Global 500 company with over 425 million mobile subscribers and operating revenues amounting to US$72.5 billion in 2024, brings immense infrastructure strength, technical support, and national reach to the project. By aligning with&nbsp;Jianzhi, China Telecom will further extend its strategic presence in the digital education space through seamless cloud-based delivery. Jianzhi's cloud-ready educational content and platforms will support the joint development of new cloud-native applications and services tailored to the needs of learners and institutions nationwide.

Jianzhi Education Technology Announces It Had Partnered With China Telecom, Collaboration Aims To Reshape The Future Of Education By Embedding Cutting-Edge AI-Generated Content And Digital Human Technologies Into The Learning Experience

CORRECTION: NRG Energy Q1 Adj. EPS $2.62 Beats $1.49 Estimate, Sales $8.59B Beat $7.83B Estimate

WIIM

RMTI

Rockwell Medical shares are trading higher after the company reported better-than-expected Q1 financial results.

MEGL

Magic Empire Global shares are trading lower after the company announced it filed a prospectus for the offer and sale of up to 15 million shares.

Guggenheim analyst Curry Baker maintains DraftKings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DKNG#NASDAQ">DKNG</a>) with a Buy and lowers the price target from $61 to $60.

DKNG

Guggenheim Maintains Buy on DraftKings, Lowers Price Target to $60

Management

NWBI

Northwest Bancshares Announces Timothy B. Fannin Has Stepped Down As Board Chair, And Has Been Succeeded By Vice Chair Timothy M. Hunter

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades, downgrades and initiations, please see our <a href="https://www.benzinga.com/analyst-stock-ratings">analyst ratings page</a>.
<ul class="wp-block-list">
<li>Canaccord Genuity analyst Richard Close downgraded DocGo Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DCGO#NASDAQ">DCGO</a>) from Buy to Hold and lowered the price target from $5 to $1.45. DocGo shares closed at $1.40 on Friday. <a href="https://www.benzinga.com/quote/dcgo/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Barrington Research analyst Michael Petusky downgraded the rating for ModivCare Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MODV#NASDAQ">MODV</a>) from Outperform to Market Perform. ModivCare shares closed at $1.17 on Friday. <a href="https://www.benzinga.com/quote/modv/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>JP Morgan analyst Ekaterina Knyazkova downgraded Amphastar Pharmaceuticals, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMPH#NASDAQ">AMPH</a>) from Overweight to Neutral and cut the price target from $45 to $30. Amphastar Pharma shares closed at $24.11 on Friday. <a href="https://www.benzinga.com/quote/amph/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Bernstein analyst Zhihan Ma downgraded the rating for Target Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TGT#NYSE">TGT</a>) from Market Perform to Underperform and lowered the price target from $97 to $82. Target shares closed at $96.40 on Friday. <a href="https://www.benzinga.com/quote/TGT/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Goldman Sachs analyst Stephen Laszczyk downgraded Warner Music Group Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WMG#NASDAQ">WMG</a>) from Buy to Neutral and slashed the price target from $35 to $28. Warner Music shares closed at $27.36 on Friday. <a href="https://www.benzinga.com/quote/WMG/analyst-ratings">See how other analysts view this stock.</a></li>
</ul>
Considering buying TGT stock? Here&#8217;s what analysts think: 
<figure class="wp-block-image size-large is-resized"><img loading="lazy" decoding="async" width="1024" height="577" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/12092527/image-126-1024x577.png" alt="" class="wp-image-911928" style="width:600px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/12092527/image-126-1024x577.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/12092527/image-126-300x169.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/12092527/image-126-768x432.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/12092527/image-126.png 1103w" sizes="(max-width: 1024px) 100vw, 1024px" /></figure>
Read This Next: 
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/analyst-ratings/price-target/25/05/45342900/5-stock-picks-last-week-from-wall-streets-most-accurate-analysts-5">5 Stock Picks Last Week From Wall Street&#8217;s Most Accurate Analysts</a> </li>
</ul>
Photo via Shutterstock

Downgrades

Pre-Market Outlook

Trading Ideas

AMPH

DCGO

MODV

This Target Analyst Turns Bearish; Here Are Top 5 Downgrades For Monday

Superior Industries International shares are trading lower after the company reported worse-than-expected Q1 EPS results and announced it is withdrawing its FY25 guidance.

Inter &amp; Co (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INTR#NASDAQ">INTR</a>) reported quarterly earnings of $0.11 per share which missed the analyst consensus estimate of $0.12 by 8.33 percent. This is a 22.22 percent increase over earnings of $0.09 per share from the same period last year. The company reported quarterly sales of $313.81 million which missed the analyst consensus estimate of $327.02 million by 4.04 percent. This is a 10.88 percent increase over sales of $283.02 million the same period last year.

Earnings Misses

INTR

Inter & Co Q1 GAAP EPS $0.11 Misses $0.12 Estimate, Sales $313.81M Miss $327.02M Estimate

In the face of ongoing trade tensions,&nbsp;Apple Inc.&nbsp;(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AAPL#NASDAQ">AAPL</a>) is reportedly contemplating raising the prices for its forthcoming fall iPhone models, while also planning to introduce new features and design changes.
What Happened: The iPhone maker is planning a price hike but is keen to dispel any notion that a possible price increase is tied to U.S. tariffs on Chinese goods, where most of its devices are assembled, according to a <a href="https://www.wsj.com/tech/apple-iphone-price-increase-2eaebb14">report</a> by The Wall Street Journal on Monday.
Facing supply chain pressures, Apple is considering raising iPhone prices to protect profits, while seeking non-tariff reasons to justify the hike, though new feature details remain unclear. Notably, the company is preparing to launch new iPhones this fall, which will include design updates such as an ultrathin profile.
CEO Tim Cook has been navigating the U.S.-China trade tensions, which threaten Apple's supply chain. In response, he has increased inventory levels and moved some U.S.-bound manufacturing to India. However, production of Apple's high-end models like the Pro and Pro Max will largely remain in Chinese factories, as India's infrastructure and technical capacity are not yet advanced enough to support large-scale production on par with China's current capabilities, sources told the publication.
Apple is also exploring the possibility of shifting some iPhone production to the U.S., a move that could take several years. In the meantime, its shift toward manufacturing smartphones in India for export to the U.S. is expected to gain momentum.
SEE ALSO:&nbsp;<a href="https://benzinga.com/25/05/45343504/judge-halts-arizona-land-transfer-to-rio-tinto-citing-native-appeal" target="_blank" rel="noreferrer noopener">Judge Halts Arizona Land Transfer To Rio Tinto Citing Native Appeal</a>
Why It Matters: Apple&#8217;s potential price hike comes amid a series of strategic moves and product innovations. Earlier in May, Apple&#8217;s CEO, Tim Cook, discussed the possibility of <a href="https://www.benzinga.com/markets/25/05/45162929/tim-cook-tells-commerce-secretary-lutnick-how-apple-could-bring-iphone-manufacturing-to-us">relocating iPhone</a> production to the U.S. with U.S. Commerce Secretary Howard Lutnick. This was followed by the news of Apple bracing for a $900 million <a href="https://www.benzinga.com/markets/25/05/45185355/apple-braces-for-900-million-tariff-impact-tim-cook-discusses-potential-iphone-manufacturing-shift-to-us-with-lutnick-and-more-this-week-in-appleverse">tariff impact</a>, as revealed by Cook during the company&#8217;s fiscal second-quarter earnings call.
Notably, Apple is reportedly planning a <a href="https://www.benzinga.com/tech/25/05/45338324/apples-2027-vision-foldable-iphones-smart-glasses-and-ai-innovations">significant year </a>in 2027, with plans to introduce a range of innovative devices and features, including a foldable iPhone and smart glasses. These developments highlight Apple&#8217;s ongoing efforts to navigate trade tensions while maintaining its commitment to innovation and customer satisfaction.
Despite these strategies, Apple may still find it challenging to counterbalance China tariff costs solely through supplier savings, potentially affecting its profit margin unless it can increase prices. However, executives are wary about attributing price increases to tariffs, after the White House slammed Amazon Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMZN#NASDAQ">AMZN</a>), displaying tariffs beside its product prices and calling it a &#8216;hostile act&#8217;.
Apple holds a momentum rating of 49.76% and a quality rating of 82.46%, according to&nbsp;<a href="https://www.benzinga.com/quote/AAPL" target="_blank" rel="noreferrer noopener">Benzinga's Proprietary Edge Rankings</a>. For an in-depth report on more stocks and insights into growth opportunities,&nbsp;<a href="https://www.benzinga.com/screener/top-momentum-stocks" target="_blank" rel="noreferrer noopener">sign</a>&nbsp;<a href="https://www.benzinga.com/screener/top-momentum-stocks" target="_blank" rel="noreferrer noopener">up for Benzinga Edge.</a>
Apple stock has declined 18.59% during the year-to-date period.
<ul class="wp-block-list">
<li>READ MORE:&nbsp;<a href="https://benzinga.com/news/25/05/45338404/charlie-mungers-financial-success-advice-i-avoided-standard-ways-of-failing-because-my-game-in-life-was-always-to-avoid-all-standard-ways-of-failing" target="_blank" rel="noreferrer noopener">Charlie Munger&#8217;s Financial Success Advice: &#8216;I Avoided Standard Ways Of Failing, Because My Game in Life Was Always To Avoid All Standard Ways of Failing&#8217; &#8211; Benzinga</a></li>
</ul>
Image via Shutterstock
Disclaimer:&nbsp;This content was partially produced with the help of AI tools and was reviewed and published by Benzinga editors.

Markets

AAPL

AMZN

Apple May Hike iPhone Prices This Fall, Steering Clear Of Tariff Blame: Report

CTMX

CytomX Therapeutics shares are trading higher. The company announced a $100 million offering of 76.9 million shares at $1.30 per share.

Novo Nordisk A/S (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NVO#NYSE">NVO</a>) on Monday presented data from the phase 3 REAL8 basket study investigating once-weekly Sogroya&nbsp;(somapacitan) in four different but related growth disorder indications, including small for gestational age (SGA), Turner syndrome (TS), Noonan syndrome (NS), and idiopathic short stature (ISS) <a target="_blank" href="https://www.benzinga.com/general/health-care" rel="noreferrer noopener">under one trial protocol</a>.
In REAL8, pre-pubertal children with NS, TS, or ISS were randomized to receive either once-weekly Sogroya&nbsp;(somapacitan) 0.24 mg/kg/week or once-daily somatropin 0.050 mg/kg/day.
Children born SGA were <a target="_blank" href="https://www.novonordisk.com/content/nncorp/global/en/news-and-media/news-and-ir-materials/news-details.html?id=916003" rel="noreferrer noopener">randomized</a> to receive either somapacitan 0.24 mg/kg/week, a low dose of somatropin 0.035 mg/kg/day, or a high dose of somatropin 0.067 mg/kg/day.
Also Read: <a target="_blank" href="https://www.benzinga.com/general/health-care/25/05/45341590/trumps-drug-pricing-executive-order-could-rattle-pharma-stocksprice-cuts-up-to-80" rel="noreferrer noopener">Trump&#8217;s New Drug Pricing Executive Order Could Rattle Pharma Stocks, With Price Cuts Of Up To 80%: Novo Nordisk, Pfizer And J&amp;J Fall In Premarket</a>
The trial showed that once-weekly Sogroya was non-inferior to the once-daily growth hormone Norditropin&nbsp;(somatropin) in improving yearly growth rate (as measured by height velocity or HV at Week 52).
In addition, once-weekly Sogroya was superior to daily growth hormone in children with NS and to lower doses of daily growth hormone in children born SGA.
REAL8 data showed that Sogroya&nbsp;was well-tolerated, with no safety or tolerability issues identified compared to once-daily growth hormone.
Results from the Turner syndrome (TS) sub-study of REAL8 will be available later this year.
The REAL8 trial achieved its primary endpoints for the first three sub-studies, demonstrating that once-weekly Sogroya&nbsp;was non-inferior to once-daily growth hormone treatment at Week 52 across the three indications presented:
<ul class="wp-block-list">
<li>In children born SGA, Sogroya&nbsp;demonstrated superior estimated mean HV when compared with a lower dose (0.035 mg/kg/day) of somatropin (11.0 vs 9.4 cm/year) and non-inferior estimated mean HV when compared with a higher dose (0.067 mg/kg/day) of somatropin (11.0 vs 11.1 cm/year).</li>
<li>Sogroya&nbsp;demonstrated superior estimated mean HV in children with NS compared with somatropin (10.4 vs 9.2 cm/year).</li>
<li>Sogroya&nbsp;demonstrated non-inferior estimated mean HV in children with ISS compared with daily somatropin (10.5 vs 10.5 cm/year).</li>
<li>In April 2025, based on the data from REAL8 and REAL9, the three indications (SGA, NS, and ISS) were submitted for regulatory review in both the EU and the U.S.</li>
</ul>
Price Action: NVO stock is down 3.00% to $63.80 during the premarket session at the last check on Monday.
Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/analyst-ratings/price-target/25/05/45328107/shopify-shows-strong-global-momentum-but-guidance-raises-questions-on-profitability-path" target="_blank" rel="noreferrer noopener">Shopify Shows Strong Global Momentum, But Guidance Raises Questions On Profitability Path</a></li>
</ul>
Image via Shutterstock

Large Cap

Health Care

Movers

Novo Nordisk's Sogroya Supports Effective Weekly Alternative To Daily Hormone Therapy Across Three Growth Disorders

Guggenheim analyst Debjit Chattopadhyay maintains Intellia Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NTLA#NASDAQ">NTLA</a>) with a Buy and lowers the price target from $55 to $45.

NTLA

Guggenheim Maintains Buy on Intellia Therapeutics, Lowers Price Target to $45

Press Releases

Real Estate

NexPoint Provides Update on UDF IV's Proposed Merger with Ready Capital, Plans to Submit Competing Proposal

NexPoint Submits Competing Proposal for UDF IV with Improved Shareholder Economics, Awaits Engagement from UDF IV Board of Trustees

NexPoint Diversified Real Estate Trust Announces Investor Update Call

NexPoint Provides Update on UDF IV Proposal and Special Meeting as Ready Capital Earnings Report Heightens Concerns About Proposed Merger

NexPoint Diversified Real Estate Trust Announces Record Date and Date of 2025 Annual Meeting of Shareholders

KBW Announces Index Rebalancing for First-Quarter 2025

NexPoint Hospitality Trust and NexPoint Diversified Real Estate Trust Announce Expected Closing Date for Going Private Transaction

NexPoint Hospitality Trust Completes Going Private Transaction with NexPoint Diversified Real Estate Trust

Dividends

NexPoint Diversified Real Estate Trust Announces Quarterly Distribution

NexPoint Diversified Real Estate Trust Announces Preferred Share Distribution

CLPR

NXDT

TSXV:NHT

TSXV:NHT.U

American Assets Trust

Armada Hoffler Properties, Inc. Common Stock

Armada Hoffler Properties

Alexander & Baldwin, Inc. Common Stock REIT Holding Company

Alexander & Baldwin

Broadstone Net Lease

CTO Realty Growth

Essential Properties Realty Trust, Inc. Common Stock

Essential Properties

Empire State Realty OP, L.P. Series ES Operating Partnership Units Representing Limited Partnership Interests

Empire State Realty OP

Generation Income Properties Inc. - Common stock

Generation Income

Global Net Lease

Gladstone Commercial Corporation - Real Estate Investment Trust

Gladstone Commercial

Medalist Diversified REIT, Inc. - Common Stock

Medalist Diversified REIT

Modiv Industrial, Inc. Class C Common Stock

Modiv Industrial

MacKenzie Realty Capital, Inc. - Common Stock

Mackenzie Realty Capital

One Liberty Properties, Inc. Common Stock

One Liberty Properties

Alpine Income Property Trust, Inc. Common Stock

Alpine Income Property Tr

Presidio Property Trust, Inc. - Class A Common Stock

Comments

NexPoint Diversified Real

Vendite allo scoperto

NexPoint Diversified Real (NYSE:NXDT) Azioni, Report sulle vendite allo scoperto

Le persone guardano anche

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO